Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie – which also discovers and delivers medicines in neuroscience, eye care, virology, gastroenterology, and an Allergan Aesthetics portfolio – has an option to expand the collaboration ...

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0824 ET – AbbVie raises its long-term sales outlook for ...

AbbVie and Neomorph are forming a partnership ... team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases." The acquisition deal ...